Innovation for Patients Driven by
The Potential to Forever Change How Cancer is Treated
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR TTM) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T (Auto CAR TTM) therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.
Accelerating an Expansive Portfolio
We are advancing our AlloCAR TTM portfolio acquired from Pfizer, which includes rights to 16 preclinical CAR T cell therapy targets licensed from Cellectis and Servier and U.S. rights to clinical candidates ALLO-501 and UCART19.
Allogene initiated its Phase 1 ALPHA study of ALLO-501 in 1H 2019 to assess safety and tolerability of ALLO-501 and ALLO-647, our proprietary anti-CD52 monoclonal antibody, in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). Servier is the sponsor of the UCART19 program, which is currently in Phase 1 for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).
Led by a Veteran Team
Our world-class management team has significant experience in cell therapy. Allogene co-founders include Dr. Arie Belldegrun and Dr. David Chang, who developed one of the first CAR T cell therapies approved by the U.S. Food and Drug Administration. The team has unparalleled scientific, clinical and regulatory expertise, and a track record of success.